Edition:
United States

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

74.60EUR
22 Sep 2017
Change (% chg)

€0.80 (+1.08%)
Prev Close
€73.80
Open
€73.80
Day's High
€74.65
Day's Low
€73.80
Volume
32,023
Avg. Vol
75,528
52-wk High
€75.15
52-wk Low
€49.98

Chart for

About

DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease,... (more)

Overall

Beta: 0.33
Market Cap(Mil.): €4,173.74
Shares Outstanding(Mil.): 55.95
Dividend: 0.80
Yield (%): 1.07

Financials

  Industry Sector
P/E (TTM): -- 31.44 16.08
EPS (TTM): -- -- --
ROI: -- 13.78 14.60
ROE: -- 16.62 14.03

BRIEF-DiaSorin ‍earns CE-mark extending sample claims for its Simplexa HSV 1&2 kit​

* ‍EARNS CE-MARK EXTENDING SAMPLE CLAIMS FOR DIASORIN MOLECULAR'S SIMPLEXA HSV 1 & 2 KIT​

Sep 21 2017

BRIEF-DiaSorin Q2 net profit up at EUR 33.6 mln

* Q2 NET PROFIT EUR 33.6 MILLION VERSUS EUR 29.4 MILLION YEAR AGO

Aug 03 2017

BRIEF-DiaSorin launches three primer pairs for use in molecular testing

* LAUNCHES 3 PRIMER PAIRS FOR USE IN MOLECULAR TESTING: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, AND GROUP G STREPTOCOCCUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 28 2017

BRIEF-Diasorin to acquire ELISA immunodiagnostic business portfolio from Siemens Healthineers

* TO ACQUIRE ELISA IMMUNODIAGNOSTIC BUSINESS PORTFOLIO AND ASSOCIATED ASSETS FROM SIEMENS HEALTHINEERS

Jul 25 2017

BRIEF-DiaSorin launches test Iam CBFB-MYH11 for acute myeloid leukemia

* LAUNCHES MOLECULAR DIAGNOSTIC TEST IAM CBFB-MYH11 (AVAILABLE WORLDWIDE EXCEPT UNITED STATES) FOR DIAGNOSIS OF ONE OF THE GENETIC CAUSES OF ACUTE MYELOID LEUKEMIA Source text: http://reut.rs/2tZeE1p Further company coverage: (Gdynia Newsroom)

Jul 10 2017

BRIEF-Diasorin presents its 2017-2019 industrial plan

* DIASORIN WILL CONTINUE TO LOOK FOR POTENTIAL ACQUISITIONS, FOCUSING ON TARGET THAT WILL ALLOW GROUP TO EXPAND ITS CUSTOMER BASE AND ITS PRESENCE IN STRATEGIC MARKETS

Jun 26 2017

BRIEF-DiaSorin to collaborate with Tecan in platform development

* UNDER COLLABORATION DIASORIN WILL MAKE USE OF TECAN'S FLUENT LABORATORY AUTOMATION SOLUTION AS ITS NUCLEIC ACID EXTRACTION PLATFORM Source text: http://reut.rs/2sI1hzF Further company coverage: (Gdynia Newsroom)

Jun 23 2017

BRIEF-Diasorin, Qiagen to develop tests for Diasorin's family of analyzers

* Signs collaboration with Qiagen to expand liaison test menu through adoption of select Qiagen assays Further company coverage:

Jun 22 2017

BRIEF-Diasorin signs collaboration with QIAGEN to expand LIAISON test menu

* SIGNS COLLABORATION WITH QIAGEN TO DEVELOP NEW TESTS FOR DIASORIN’S LIAISON FAMILY OF ANALYZERS BASED ON REVIEW AND SELECTION PROCESS INVOLVING QIAGEN’S ASSAY TECHNOLOGIES Source text: http://reut.rs/2sFOaPL Further company coverage: (Gdynia Newsroom)

Jun 22 2017

BRIEF-DiaSorin launches test Liaison SHBG to diagnose androgen-related disorders

* LAUNCHES TEST LIAISON SHBG FOR DIAGNOSIS OF DISORDERS RELATED TO THE ANDROGEN HORMONES

May 23 2017

Earnings vs. Estimates